Autism stem cell therapy is now under investigation as an experimental treatment. When a facility guarantees you that you can make improvements or that your condition may be resolved with the same stem cell therapy, be sceptical! In actual medicine, outcomes are not guaranteed and cures are not accessible. However, the bulk of these clinics are not FDA-approved, and each clinic or hospital promotes its own approach to care, which leaves parents in a state of confusion about how to compare their treatment options.
How did stem cell treatment for brain disorders begin?
Where does autism fit into all of this?
When children are young, ASD is not detected as a consequence of language difficulties, poor coping abilities, or repetitive or inflexible behaviours. The number of autistic children has grown in developing countries; in the United States, the prevalence of autism has climbed from 1 in 125 to 1 in 59 in less than a decade (CDC). We’ve reached a point where anybody with small children knows someone who has an autistic child.
Consequences of stem cells or bone marrow transplantation
- Throat and mouth soreness. Mucositis is a short-term adverse effect of chemotherapy and radiation (inflammation of mouth sores)
- Nausea and Vomiting
- Hepatic veno-occlusive disease (VOD).
- Hemorrhage and transfusions.
- Graft amputation
- Interstitial pneumonitis and associated lung problems.
- Graft Versus Host illness.
What is the theoretical foundation for using stem cells to treat autism?
Autism research now focuses on reversing such defects with antibiotic, anti-inflammatory, and hyperbaric oxygen therapy. Unfortunately, none of these therapies addresses the underlying causes of oxygen deficiency and intestinal infection.
Autism has been strongly linked to pro-inflammatory and neuro-inflammatory cytokines and the thymus, such as macrophage-derived chemokine and activation-regulated chemokine (MDC). Autism has a significant impact on the therapy of mesenchymal stem cells derived from umbilical cord tissue (TARC). Numerous clinical investigations have showed that intravenous treatment of umbilical cord MSCs reduces inflammation. Reduced autistic inflammation has been shown to alleviate autism symptoms.
Numerous roadblocks stand in the way of therapeutic viability and treatment success. To begin, stem cell treatment, being a relatively new invention, has a number of technical hurdles when applied to the human body.
Tumor risk, particularly the danger of viruses employed in certain therapies causing tumours in recipients, is a significant safety issue and problem. Associating transplanted stem cells with the surrounding fibre may also be challenging. The lack of umbilical cord blood in the Indian understanding is often a source of contention.
There have been a few examples recorded in India where autologous bone marrow or comparable blood has been utilised for the infusion – these will, however, be negative, and this cannot be beneficial for people, according to technical requirements. It’s worth noting that cord blood infusion involves very difficult and precise procedures. All precautionary measures must be rigorously followed, otherwise the method will be inefficient.